Schizophrenia Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The schizophrenia market size has grown strongly in recent years. It will grow from $5.82 billion in 2024 to $6.11 billion in 2025 at a compound annual growth rate (CAGR) of 5%. The growth in the historic period can be attributed to growing demand for effective treatments, mental health awareness, government initiatives, growing research and development.

The schizophrenia market size is expected to see strong growth in the next few years. It will grow to $7.54 billion in 2029 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to growing personalized medicine, growing digital health solutions, growing improved antipsychotic medications, expanding access to healthcare services. Major trends in the forecast period include new drug development, growing emphasis on early intervention, recovery-oriented cares, expanding clinical trials pipeline for schizophrenia treatments.

The growing prevalence of mental illness is expected to fuel the expansion of the schizophrenia market in the future. Mental illness encompasses a broad spectrum of mental health conditions that impact a person's cognition, emotions, mood, and behavior, significantly affecting their daily life and interpersonal relationships. The rise in mental health cases has spurred advancements in the treatment of schizophrenia and the development of new medications, thereby contributing to the market's growth. For instance, as of March 2023, data from the National Institute of Mental Health (NIMH), a department of health and human services in the United States, indicated that an estimated 57.8 million adults aged 18 and older had experienced any mental illness (AMI), constituting 22.8% of all adults in the United States. Among different age groups, young adults aged 18-25 years exhibited the highest prevalence of AMI at 33.7%, followed by those aged 26-49 years (28.1%), and individuals aged 50 and above (15%). Consequently, the escalating burden of mental illness is expected to be a driving force behind the growth of the schizophrenia market.

The increasing demand for anxiety treatment is expected to drive the growth of the schizophrenia market in the future. Anxiety treatment encompasses various therapeutic approaches and interventions designed to help individuals manage and alleviate excessive and debilitating anxiety symptoms. This treatment can be particularly beneficial for those with schizophrenia, as it addresses comorbid anxiety symptoms that often accompany the disorder and can help reduce the intensity of psychotic symptoms such as hallucinations and delusions. For example, in May 2024, a report by the American Psychiatric Association, a U.S.-based professional organization for psychologists, indicated that in 2024, 43% of adults reported feeling more anxious, up from 37% in 2023 and 32% in 2022, showing a steady rise in anxiety levels. Therefore, the growing demand for anxiety treatment is contributing to the expansion of the schizophrenia market.

Prominent companies in the schizophrenia market are embracing emerging technologies like automated psychological therapy to bolster their market presence. Automated psychological therapy involves utilizing technology, including virtual reality (VR), to offer psychological therapy in an autonomous or self-guided manner. For example, in April 2022, OxfordVR Limited, a digital therapeutic company based in Switzerland, introduced the gameChangeVR technology - a 6-week automated VR treatment that delivers cognitive behavioral therapy (CBT) within secure and immersive virtual environments. This VR-based automated psychological therapy replaces real-life therapists with a virtual coach, enabling the treatment to reach a broader range of patients. Notably, this marks the first instance where digital therapy of any kind has demonstrated efficacy in treating individuals with schizophrenia and mood disorders who experience psychotic symptoms.

In March 2023, Royalty Pharma PLC, a US-based purchaser of biopharmaceutical royalties, completed the acquisition of the royalty rights for the KarXT schizophrenia treatment from Karuna Therapeutics Inc., for a sum of $500 million. As part of this agreement, Royalty Pharma will provide PureTech with a 3% royalty on Karuna's annual sales, up to $2 billion. This acquisition also provides PureTech with additional capital to advance its internal pipeline, including ongoing clinical initiatives, with the potential for future commercialization. KarXT is an investigational oral medication specifically developed for the treatment of schizophrenia and other neurological disorders, focusing on M1/M4-preferred muscarinic agonists. Karuna Therapeutics Inc., a clinical-stage biopharmaceutical company based in the United States, specializes in the development of pharmaceuticals for psychiatric disorders and schizophrenia.

Major companies operating in the schizophrenia market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Amgen Inc., Otsuka Holdings Co. Ltd., Biogen Inc., Daiichi Sankyo Co. Ltd., Astellas Pharma Inc., Sumitomo Dainippon Pharma Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Recordati SpA, Lundbeck A/S, Neurocrine Biosciences Inc., Torrent Pharmaceutical Ltd., Alkermes PLC, Indivior PLC, Vanda Pharmaceuticals Inc., Intra-Cellular Therapies Inc., Axsome Therapeutics Inc., PsychoGenics Inc., Karuna Therapeutics Inc., Minerva Neurosciences Inc.

North America was the largest region in the schizophrenia market in 2024. The regions covered in the schizophrenia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the schizophrenia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain.

The schizophrenia market consists of revenues earned by entities by providing cognitive behavioral therapy, electroconvulsive therapy, and group counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The schizophrenia market also includes sales of risperdal, invega, zyprexa, geodon and seroquel. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Schizophrenia is a severe and long-term mental illness that significantly affects an individual's cognitive processes, emotional expression, behavior, and their perception of reality. Symptoms may include delusions, hallucinations, disordered speech, and unusual movements. The comprehensive management of schizophrenia involves a combination of pharmaceutical treatments, rehabilitation programs, and supportive services.

Schizophrenia can manifest in different forms, including catatonic schizophrenia, paranoid schizophrenia, undifferentiated schizophrenia, hebephrenic schizophrenia, residual schizophrenia, and others. Catatonic schizophrenia is a subtype characterized by severe motor disturbances, such as catatonia, immobility, and abnormal postures or movements. Treatment typically involves antipsychotic medications and supportive therapies to manage psychotic symptoms and address catatonic motor behavior. Available treatments encompass first-generation antipsychotics, second-generation antipsychotics, third-generation antipsychotics, psychotherapies, and other therapeutic drugs that can be administered through oral or injectable routes.

The schizophrenia market research report is one of a series of new reports that provides schizophrenia market statistics, including schizophrenia industry global market size, regional shares, competitors with a schizophrenia market share, detailed schizophrenia market segments, market trends, and opportunities and any further data you may need to thrive in the schizophrenia industry. This schizophrenia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.